A Phase II Study of Cyclophosphamide, Etoposide, Vincristine and Prednisone (CEOP) Alternating with Pralatrexate (P) as Front Line Therapy for Patients with Peripheral T-Cell Lymphoma (PTCL): Final Results from the T- Cell Consortium Trial

Peripheral T-cell lymphomas (PTCL) have suboptimal outcomes using conventional CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy. The anti-folate pralatrexate, the first drug approved for patients with relapsed/refractory PTCL, provided a rationale to incorporate it into the...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Haematol
Main Authors: Advani, Ranjana H., Ansell, Stephen M., Lechowicz, Mary Jo, Beaven, Anne W., Loberiza, Fausto, Carson, Kenneth R., Evens, Andrew M., Foss, Francine, Horwitz, Steven, Pro, Barbara, Brown, Lauren Pinter, Smith, Sonali M., Shustov, Andrei R., Savage, Kerry J., Vose, Julie
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5642048/
https://ncbi.nlm.nih.gov/pubmed/26627450
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.13855
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados